63 completed, 18 unknown, 5 withdrawn, 3 terminated. 28 Phase 3, 20 Phase 2, 19 Phase 4, 14 Phase 1, 12 Not applicable.
Follow Granisetron: new trials by email Literature Review of Granisetron trials Research Report on Granisetron
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Granisetron Use, Blood Pressure, and Nausea and Vomiting During Cesarean Delivery Under Spinal Anesthesia Granisetron - Hypotension, Nausea | Not yet recruiting | Kayseri City Hospital | 80 | 2026-10-15 | 2026-10-06 | |
| Granisetron Combined With Dexamethasone or Metoclopramide for PONV Prevention After Laparoscopic Cholecystectomy Granisetron - Postoperative Nausea and Vomiting (PONV) | Phase 4 | Not yet recruiting | Assiut University | 102 | 2026-03-01 | 2026-01-22 |
| Occlusal Splint Combined With Granisetron Injection for Management of Myofascial Pain Related to Temporomandibular Disorders Granisetron, lidocaine, occlusal splint - TMD, TMD/Orofacial Pain | Phase 4 | Active not recruiting | Mansoura University | 48 | 2026-01-27 | 2026-03-05 |
| A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery Palonosetron (Group P), Granisetron (Group G) - Postoperative Nausea and Vomiting, Scoliosis | Phase 4 | Completed | University of Malaya | 74 | 2025-01-06 | 2026-08-20 |
| Granisetron Versus Pethidine in Treatment of Post Spinal Shivering in Cesarean Sections Granisetron 1 Mg/mL Intravenous Solution, Pethidin - Anesthesia; Adverse Effect, Spinal and Epidural | Phase 4 | Completed | Ain Shams University | 330 | 2024-08-01 | 2025-10-02 |
| Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC Aprepitant in combination with granisetron and dexamethasone, Granisetron and dexamethasone - Hepatocellular Carcinoma | Phase 3 | Unknown | Guangxi Medical University | 300 | 2024-07-01 | 2024-01-23 |
| Comparative Study Between Intravenous Granisetron and Ondansetron on Their Effect on Hemodynamics and Shivering After Spinal Anesthesia in Elective Cesarean Delivery ondansetron, granisetron - Hemodynamic Instability and Shivering | Not applicable | Unknown | Sohag University | 100 | 2024-04-10 | 2024-05-31 |
| Postoperative Intraperitoneal Pain Management Following Laparoscopic Cholecystectomy Granisetron 1 Mg/mL Intravenous Solution, Normal saline - Post Operative Pain | Phase 3 | Completed | Future University in Egypt | 46 | 2024-02-29 | 2025-01-10 |
| Intravenous Granisetron Vs Dexmedetomidine on Postspinal in the Cesarean Section. Dexmedetomidine, Granisetron, Placebo - Postspinal Shivering | Not applicable | Unknown | Minia University | 99 | 2024-01-01 | 2025-01-09 |
| Clonidine Versus Granisetron for Shivering Prevension Clonidine Injection, Granisetron Injection, Normal Saline 10 mL Injection - Post Spinal Anesthesia Shivering | Phase 2 | Unknown | Zagazig University | 186 | 2023-03-05 | 2023-09-11 |
| Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery Aprepitant, Granisetron - Postoperative Nausea, Vomiting | Phase 4 | Unknown | Baskent University | 60 | 2022-11-24 | 2022-11-30 |
| Safety Study of Repeat Doses of SUSTOL in Adults SUSTOL - Chemotherapy-Induced Nausea and Vomiting (CINV) | Phase 4 | Unknown | Heron Therapeutics | 300 | 2022-07-06 | 2023-07-28 |
| Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section Granisetron Hydrochloride, 0.9% normal saline - Granisetron | Phase 2 / Phase 3 | Unknown | Assiut University | 102 | 2022-04-01 | 2022-04-06 |
| The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy Dezocine, Sufentanil injection, Flurbiprofen - Patient-controlled Analgesia | Not applicable | Completed | Eye & ENT Hospital of Fudan University | 129 | 2022-02-10 | 2023-08-21 |
| Granisetron Transdermal Patch System for Prevention of CINV by CapeOX Granisetron Transdermal Patch System - Chemotherapy-induced Nausea and Vomiting | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 57 | 2021-10-10 | 2022-04-13 |
| Granisetron Transdermal Patch for Prophylaxis of Delayed CINV Granisetron transdermal patch, Palonosetron, Aprepitant - Chemotherapy-induced Nausea and Vomiting (CINV) | Phase 3 | Unknown | Fudan University | 140 | 2021-06-10 | 2021-06-03 |
| Granisteron Versus Metoclopramide in Laparoscopic Cholecystectomy Granisetron - Nausea and Vomiting, Postoperative | Phase 4 | Unknown | Assiut University | 60 | 2021-05-01 | 2021-05-25 |
| Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients fosaprepitant, aprepitant, Granisetron plus dexamethasone - Chemotherapy Induced Nausea and Vomiting, Pediatric Cancer Patients | Not applicable | Unknown | Shanghai Children's Medical Center | 120 | 2021-05-01 | 2021-05-10 |
| Effects of Ondansetron, Metoclopramide and Granisetron on Perioperative Nausea and Vomiting in Patients Undergone Bariatric Surgery Metoclopramide, Ondansetron, Metoclopramide and Ondanteron - Bariatric Surgery Candidate, Perioperative Complication | Phase 3 | Completed | Shahid Beheshti University of Medical Sciences | 130 | 2021-03-01 | 2021-10-29 |
| Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) NEPA (300mg netupitant/0.5mg palonosetron), Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV), Dexamethasone, 8 mg (oral) or equivalent IV dose - Chemotherapy-induced Nausea and Vomiting | Phase 4 | Completed | Helsinn Healthcare SA | 414 | 2021-02-01 | 2025-12-02 |
Showing 20 of 93. Sign in to see all of them.
Vomiting (46) · Nausea (28) · Postoperative Nausea and Vomiting (14) · Neoplasms (5) · Lymphoma (4) · Breast Neoplasms (3) · Hypotension (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Gastroparesis (2) · Leukemia (2) · Ovarian Neoplasms (2) · Temporomandibular Joint Disorders (2) · Testicular Germ Cell Tumor (2) · Testicular Neoplasms (2)
Assiut University (6) · Kyowa Kirin Co., Ltd. (4) · Heron Therapeutics (3) · Kyowa Kirin Pharmaceutical Development Ltd (3) · Tesaro, Inc. (3) · Fudan University (2) · Gary Morrow (2) · Merck Sharp & Dohme LLC (2) · Roxane Laboratories (2) · Sanofi (2) · Teva Pharmaceuticals USA (2) · Universiti Kebangsaan Malaysia Medical Centre (2) · Ain Shams University (1) · Alliance for Clinical Trials in Oncology (1) · Astellas Pharma Inc (1)
United States (32) · Egypt (12) · China (11) · Malaysia (4) · Turkey (Türkiye) (4) · Canada (3) · Spain (3) · United Kingdom (3) · Germany (2) · Japan (2) · Switzerland (2) · Taiwan (2) · Czechia (1) · Greece (1) · India (1)
Dennis Vargo, MD (3) · Gary R. Morrow, PhD, MS (2) · James Kissling, M.D. (2) · Stuart J Mair (2) · Abdelrhman Alshawadfy, M.D (1) · Agustin Garcia (1) · Ahmed A Mohamed, M.D (1) · Alex Molasiotis, prof. (1) · Alfonso Gurpide (1) · Amr M Helmy, M.D (1) · Andrew Grigg, Professor (1) · Atul P Kulkarni, MD Anaes (1)
PMID 26272769, PMID 10690153, PMID 11050519, PMID 11773155, PMID 12562658, PMID 12761013, PMID 12770663, PMID 12906958, PMID 15471273, PMID 15915040, PMID 16198982, PMID 16306743, PMID 19135415, PMID 19205754, PMID 19663845, PMID 20038221, PMID 20049561, PMID 20835873, PMID 2164935, PMID 22563089, PMID 22915657, PMID 23716765, PMID 24106351, PMID 24276953, PMID 25971957, PMID 26272768, PMID 26289588, PMID 26634569, PMID 26921245, PMID 26997579, PMID 27188385, PMID 27410922, PMID 27454663, PMID 27826874, PMID 28455599, PMID 29424008, PMID 30409186, PMID 30932170, PMID 31329922, PMID 31574878, PMID 32467512, PMID 3354872, PMID 33558725, PMID 33735476, PMID 34002866, PMID 34086350, PMID 37368100, PMID 37394627, PMID 38323173, PMID 38955285
2005 (1), P01CA049605 (1), P30CA022453 (1), R01GM123330 (1), U10CA031946 (1), U10CA037420 (1), U10CA101165 (1)